Aclaris Therapeutics Inc (NASDAQ:ACRS) – Jefferies Group issued their Q1 2017 earnings per share estimates for shares of Aclaris Therapeutics in a report released on Wednesday. Jefferies Group analyst D. Steinberg anticipates that the firm will earn ($0.61) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $36.00 target price on the stock. Jefferies Group also issued estimates for Aclaris Therapeutics’ Q2 2017 earnings at ($0.76) EPS, Q3 2017 earnings at ($0.90) EPS, Q4 2017 earnings at ($1.06) EPS, FY2017 earnings at ($3.33) EPS, FY2018 earnings at ($3.36) EPS, FY2019 earnings at ($0.14) EPS and FY2020 earnings at $2.30 EPS.
Several other research firms also recently weighed in on ACRS. Guggenheim boosted their target price on shares of Aclaris Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, March 15th. Leerink Swann started coverage on shares of Aclaris Therapeutics in a research report on Tuesday, November 29th. They set an “outperform” rating on the stock. Finally, Zacks Investment Research raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a research report on Wednesday, March 1st. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $36.25.
Your IP Address:
Aclaris Therapeutics (NASDAQ:ACRS) opened at 28.88 on Monday. Aclaris Therapeutics has a 52-week low of $14.12 and a 52-week high of $33.25. The firm has a 50-day moving average of $28.79 and a 200 day moving average of $26.33. The company’s market capitalization is $618.96 million.
Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Wednesday, March 15th. The company reported ($0.49) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.10.
In other news, major shareholder Ventures Fund Vii L.P. Vivo sold 425,000 shares of the company’s stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $30.82, for a total value of $13,098,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Anand Mehra sold 750,000 shares of the company’s stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $28.25, for a total transaction of $21,187,500.00. The disclosure for this sale can be found here. 46.40% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in ACRS. Alyeska Investment Group L.P. purchased a new stake in shares of Aclaris Therapeutics during the fourth quarter valued at $2,656,000. Rock Springs Capital Management LP raised its stake in shares of Aclaris Therapeutics by 1.6% in the third quarter. Rock Springs Capital Management LP now owns 1,016,000 shares of the company’s stock valued at $26,020,000 after buying an additional 16,000 shares during the last quarter. Perceptive Advisors LLC purchased a new stake in shares of Aclaris Therapeutics during the fourth quarter valued at $34,219,000. Marshall Wace LLP raised its stake in shares of Aclaris Therapeutics by 286.4% in the fourth quarter. Marshall Wace LLP now owns 466,734 shares of the company’s stock valued at $12,667,000 after buying an additional 345,934 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Aclaris Therapeutics during the fourth quarter valued at $209,000. 61.94% of the stock is currently owned by institutional investors and hedge funds.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).
Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.